Accelleron and ABB have both reported strong financial results for the latest reporting period. The short-term reverse convertible on the two stocks offers attractive yield opportunities.

The price of gold has risen significantly since the beginning of the year. With the capital protection note on the Swisscanto Gold ETF, investors participate in rising gold prices, provided the 122% knock-out-barrier is not touched during the term. In additon, they benefit from 100% capital protection at maturity.

The financial results announced by Barry Callebaut, Partners Group and Richemont prompted mixed reactions on stock markets.

The planned US tariffs on Brazilian goods are likely to push up the price of many popular food items.

Starting next week, the earnings of US stock market heavyweights are expected to set the tone on Wall Street. Communications and technology companies are once again expected to deliver strong results.

Global stock markets have experienced a volatile six months. Nevertheless, the SMI closes the first half-year on a positive note. 

The importance of women's elite sport is growing worldwide. This is reflected in fans' excitement for the Women's European Football Championship, which starts in Basel on 2 July. An increasing number of sponsors are recognising this potential and expanding their partnerships with female athletes.

Advances in artificial intelligence are driving demand for high-performance data centres. Suppliers such as ABB, Schneider Electric and Siemens could benefit from this trend.

In uncertain market phases, products offering capital protection are particularly sought after. The capital protection certificate on Alcon, Kühne + Nagel and Sika offers a minimum repayment of 96% at maturity. In addition, investors participate in the positive performance of the underlying.

Since Donald Trump's re-election as US President, the outlook for the global healthcare sector has deteriorated. In this environment, investment instruments that offer both a safety net and attractive yield opportunities are in demand. With the ZKB bonus certificate on five Swiss pharmaceutical stocks, investors participate in the potential of the underlying securities without being fully exposed to market fluctuations.